LOW-DOSE CYCLOSPORINE A (1, 2 OR 3 MG/KG/DAY) IN A LARGE SERIES OF MODERATE PSORIASIS PATIENTS - PRELIMINARY-RESULTS

被引：0
|
作者：
DERIE, MA
TEGELBERG, MJAM
MEINARDI, MMHM
FABER, WR
WITKAMP, L
BOS, JD
VANVLOTEN, WA
机构：
[1] UNIV AMSTERDAM,ACAD MED CTR,DEPT DERMATOL,1105 AZ AMSTERDAM,NETHERLANDS
[2] STATE UNIV UTRECHT HOSP,DEPT DERMATOL,3511 GV UTRECHT,NETHERLANDS
[3] SANDOZ LTD,DEPT DERMATOL,UDEN,NETHERLANDS
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 1989年 / 93卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：307 / 307
页数：1
相关论文
共 50 条
  • [41] Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (Id) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours
    Stradella, A.
    Johnson, M. L.
    Goel, S.
    Chandana, S. R.
    Galsky, M. D.
    Calvo, E.
    Moreno, V.
    Park, H.
    Arkenau, H. -T.
    Cervantes, A.
    Farinas Madrid, L.
    Mileshkin, L.
    Plummer, R.
    Evans, J.
    Horvath, L.
    Prawira, A.
    Pelham, R. J.
    Mu, S.
    Andreu-Vieyra, C.
    Barve, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 166 - +
  • [42] Ixekizumab impact on the skin-related relationship problems of patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2,-3)
    Warren, R. B.
    Cather, J.
    Ohtsuki, M.
    Bleakman, A. Potts
    Burge, R.
    Zhu, B.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 77 - 78
  • [43] Deucravacitinib Improves Dermatology Life Quality Index (DLQI) in Patients with Moderate to Severe Psoriasis: Results fromthe Phase 3 POETYK PSO-1 and PSO-2 Trials
    Augustin, Matthias
    Strober, Bruce
    Armstrong, April
    Beaumont, Jennifer
    Pham, Tan
    Hudgens, Stacie
    Zhuo, Joe
    Becker, Brandon
    Banerjee, Subhashis
    Kisa, Renata
    Papp, Kim
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 112 - 112
  • [44] Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
    Armstrong, April W.
    Augustin, Matthias
    Beaumont, Jennifer L.
    Pham, Tan P.
    Hudgens, Stacie
    Gordon, Kenneth B.
    Zhuo, Joe
    Becker, Brandon
    Zhong, Yichen
    Kisa, Renata M.
    Banerjee, Subhashis
    Papp, Kim A.
    DERMATOLOGY AND THERAPY, 2024, 14 (08) : 2235 - 2248
  • [45] Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials
    Augustin, Matthias
    Strober, Bruce
    Armstrong, April W.
    Beaumont, Jennifer
    Pham, Tan P.
    Hudgens, Stacie
    Zhuo, Joe
    Becker, Brandon
    Banerjee, Subhashis
    Kisa, Renata M.
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB156 - AB156
  • [46] LOW-DOSE CLADRIBINE (2-CDA) (2MG/M2S.Q.DAY 1-7) NORMALIZES CYTOPENIA IN HAIRY-CELL LEUKEMIA (HCL) AS QUICK AS STANDARD-DOSE WITH LESS LYMPHOPENIA - NO IMPROVEMENT BY GM-CSF
    JULIUSSON, G
    LILIEMARK, J
    BLOOD, 1994, 84 (10) : A462 - A462
  • [47] A Phase 2b dose-ranging trial of baricitinib, an oral JAM 1/JAK 2 inhibitor, in patients with moderate-to-severe psoriasis: Results from the randomized withdrawal and re-treatment periods
    Papp, Kim
    Menter, Alan
    Raman, Mani
    Janes, Jonathan
    Disch, Damon
    Macias, William
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S7 - S7
  • [48] Analyzing low-dose prednisone, 3-10 mg/day, as a disease modifying anti-rheumatic drug (DMARD) over 48 weeks in routine care of patients with rheumatoid arthritis, according to efficacy and weight change
    Pincus, T
    Willoughby, J
    Sokka, T
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 265 - 265
  • [49] Effectiveness of low-dose indinavir/ritonavir at 400/100 mg twice a day with 2 nucleoside reverse transcriptase inhibitors in nonnucleoside reverse transcriptase inhibitor-experienced HIV-infected patients in India - 1-year follow-up
    Patel, Atul K.
    Patel, Ketan K.
    Patel, Jagdish K.
    Sharma, Rakesh L.
    Ranjan, Rajiv R.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) : 123 - 126
  • [50] Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
    Egeberg, Alexander
    Wu, Jashin J.
    Korman, Neil
    Solomon, James A.
    Goldblum, Orin
    Zhao, Fangyi
    Mallbris, Lotus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (01) : 104 - +
12345